Biotage
140,8
SEK
+0,07 %
Mindre end 1K følgere
BIOT
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Overview
Ownership
Investor consensus
+0,07%
+44,63%
+0,93%
-12,44%
-15,18%
-14,92%
-30,57%
+19,83%
+42,82%
Biotage operates in the biotechnology industry and focuses on the development and manufacture of products for chemical analysis and preparative chromatography. The company's products are aimed at researchers and laboratories in drug development and food analysis. The operations are international and target companies and institutions globally. Biotage was founded in 1987 and is headquartered in Uppsala.
Læs mereMarkedsværdi
11,4 mia. SEK
Aktieomsætning
171,15 mio. SEK
Omsætning
2,06 mia.
EBIT %
18,63 %
P/E
39,66
Udbytteafkast, %
1,17 %
Finanskalender
16.7
2025
Delårsrapport Q2'25
23.10
2025
Delårsrapport Q3'25
19.2
2026
Årsrapport '25
Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper

Biotage, Audiocast with teleconference, Q1'25
Biotage AB (publ) Interim report January-March 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Statement by the Board of Directors of Biotage in relation to the public offer from RWK BidCo
Biotage AB (publ) publishes Annual and Sustainability Report 2024
NOTICE OF ANNUAL GENERAL MEETING OF BIOTAGE AB (PUBL)

Biotage, Audiocast with teleconference, Q4'24
Biotage AB (publ) Year end Report January-December 2024

Biotage, Audiocast with teleconference, Q3'24
Biotage AB (publ) Interim report January-September 2024
Biotage appoints Nomination Committee
Change in number of shares and votes
Issue and re-purchase of class C shares for incentive program
Biotage AB appointment of new CEO
Change in number of votes
Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan
Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan
Biotage AB (publ) Interim report January-June 2024
